Ignite Creation Date:
2025-12-24 @ 9:46 PM
Ignite Modification Date:
2026-01-02 @ 4:13 AM
Study NCT ID:
NCT05055232
Status:
COMPLETED
Last Update Posted:
2025-07-24
First Post:
2021-09-14
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer
Sponsor:
Xuanzhu Biopharmaceutical Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-12
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-15
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-08-15
Completion Date Type:
ACTUAL
First Submit Date:
2021-09-14
First Submit QC Date:
None
Study First Post Date:
2021-09-24
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-07-21
Last Update Post Date:
2025-07-24
Last Update Post Date Type:
ACTUAL